Medicare drug price negotiations expand to hospital-administered Part B drugs for the first time

Negotiated prices for the third round of Medicare drugs take effect — the first time Part B (hospital-administered) drugs enter the negotiation program. The round targets high-cost infusion drugs and biologics administered in physician offices and hospitals. Medicare negotiation now reaches clinical settings for the first time, beyond retail pharmacies. The OBBBA's expanded orphan drug exclusion may limit the pool of eligible drugs.